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Background: In recent years advances have been made in the investigative methods of molecular background of
canine heart disease. Studies have been conducted to identify specific genes which, when pathologically expressed,
could lead to the dysfunction of the canine heart or are correlated with heart failure. For this purpose genome
wide microarray experiments on tissues from failing hearts have been performed. In the presented study a whole
genome microarray analysis was used for the first time to describe the transcription profile of peripheral blood nuclear
cells in dogs with heart failure. Dogs with recognized heart disease were classified according the ISACHC (International
Small Animal Cardiac Health Council) classification scheme as class 1 (asymptomatic) - 13 dogs, class 2 (mild to moderate
heart failure) - 13 dogs and class 3 (severe heart failure) - 12 dogs. The control group consisted of 14 healthy dogs. The
clinical picture of the animals included: animal history, clinical examination, echocardiographic examination and where
applicable electrocardiographic and radiographic examinations.
Results: In the present study we identified four sets of differentially expressed genes, namely heart-failure-specific
genes and ISACHC1-specific genes, ISACHC2-sepcific genes and ISACHC-3 specific genes. The most important set
consisted of genes differentially expressed in all dogs with heart failure, despite the ISACHC stage. We identified
71 heart-failure-specific genes which were involved in two statistically significant receptor signalling pathways,
namely angiotensinR - > CREB/ELK-SRF/TP53 signalling and ephrinR - > actin signalling. The number of
ISACHC1-specific genes was 83; ISACHC2-specific genes - 1247 and ISACHC3-specific - 200.
Conclusions: The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failure seems to
reflect the presence of clinical signs of the disease in patients based on the observation that the largest number
of differentially expressed genes was identified in ISACHC 2 group of patients. This group consists of dogs just
starting to show clinical signs of heart failure. A set of genes was also found to have changed expression in all
dogs with heart failure, despite the stage of the disease.
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In recent years some advances have been made in the
methods of investigation of the molecular background of
canine heart disease. The etiopathogenesis of one of the
most frequent heart diseases, myxomatous valve disease,
in dogs may be different compared to humans although
some similarities have been noted [1]. Some research has
been conducted to identify specific genes which, when
pathologically expressed, could lead to the dysfunction of* Correspondence: magda.loj@gmail.com
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unless otherwise stated.the canine heart or are correlated with heart failure. For
this purpose genome wide microarray experiments on
tissues from failing hearts have been performed. Their
results revealed that expression of some genes differ
between tissue samples from failing hearts and healthy
hearts, including: the matrix metalloproteinases and their
tissue inhibitors (mainly MMP9, MMP1, MMP2, TIMP1,
TIMP3) as well as genes involved in Ca2+ handling in car-
diomyocytes, e.g. genes encoding the components of the
cardiac ryanodyne receptor (RyR2) [2-6]. Other examples
of differentially expressed genes are TGF-β (TGF-βR2,
TGF-βR3) and serotonin receptors (5HT-R2B) [2]. The
genome pattern of heart tissues from dogs suffering from
heart failure were also investigated with the Real-timeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The number of differentially expressed genes in
dogs with different ISACHC stages of heart disease
Name of group ISACHC 2 ISACHC 1 Healthy dogs
ISACHC 3 2140 696 1170
ISACHC 2 - 3499 2964
ISACHC 1 - - 426
Hulanicka et al. BMC Genomics 2014, 15:509 Page 2 of 11
http://www.biomedcentral.com/1471-2164/15/509PCR method and the level of proteins encoded by differ-
entially expressed genes was examined by immunohisto-
chemical techniques. These findings gave similar results
and pointed out different expression of extracellular
matrix (ECM) genes, TGF-β receptors and thyroid hormone
receptors (TRβ1 and TRβ2) in failing hearts compared to
healthy control tissues [7-12].
The most important obstacle of the mentioned types
of studies is access to diagnostic material. That is why
researchers are attempting to investigate gene expression
of peripheral blood nuclear cells taken from patients
with cardiac disease. Blood nuclear cells are not a perfect
source of diagnostic material in patients with heart fail-
ure but easy access makes them a very interesting source
of potential disease markers. It has turned out that iden-
tification of such markers is possible since Wang et al.
described the prognostic value of B-natriuretic peptide
(BNP) in humans [13]. The results of a few studies sug-
gest that expression of Na + −Ca2+ exchanger (NCX-1)
gene in peripheral blood nuclear cells could have prog-
nostic or diagnostic value [14,15]. The other genes pro-
posed as genomic markers in dogs are phospholamban
(PLN) and haematopoietic lineage cell-specific protein 1
associated protein X-1 (HAX-1). Fonfara et al. also
pointed out that the blood cells of dogs with heart fail-
ure could be appropriate material for searching for gen-
omic markers. Their results showed increased levels of
proinflammatory cytokines (Il-1, −2, −8, INF), MMP-1,
MMP-3 and TIMP-3 and decreased levels of TNF-10, Il-
10, TGF-b1, TIMP-1 and TIMP-2 in dogs with congest-
ive heart failure [16].
In the present paper a whole genome microarray ana-
lysis was used for the first time to describe the transcrip-
tion profile of peripheral blood nuclear cells in dogs
with heart failure. The potential identification of any
prognostic marker of canine cardiac disease would be of
great importance since it may not only give new insight
into the pathogenesis or staging of the disease but also
help in the effective planning of treatment.
Results
The number of differentially expressed genes
Comparison of gene expression between all study groups
(healthy dogs, ISACHC 1, ISACHC 2, ISACHC 3) re-
vealed 4579 differentially expressed transcripts. Using
the Tukey's HSD Post-hoc test it was possible to identify
differentially expressed transcripts between individual
study groups (Table 1).
Heart failure specific and ISACHC stage specific genes
The next step of our analysis was to identify heart-failure-
specific genes. This means genes which were differentially
expressed in all dogs with heart disease, despite the
stage of the disease. The comparison between healthy andISACHC 1 group revealed 426 differentially expressed
transcripts; between healthy and ISACHC 2 dogs revealed
2964 differentially expressed transcripts and between
healthy and ISACHC 3 dogs revealed 1170 differentially
expressed transcripts. Among these three sets of differen-
tially expressed genes there were 117 common transcripts.
However, since some genes are represented on the array
by more than one spot, we verified the consistency of dif-
ferential expression in all the spots representing the same
genes to eliminate false positive results. Moreover, the on-
tologies of all the transcripts are not known. Taking into
consideration these two facts, a list of 71 heart - failure -
specific genes of known ontologies was obtained (Table 2).
The direction of changes in expression (up or down) of all
71 genes was the same in each disease stage. If a gene was
down-regulated, this means that it was down regulated in
all three comparisons (healthy vs ISACHC 1; healthy vs
ISACHC 2; healthy vs ISACHC 3).
After identifying heart - failure - specific genes we
applied the same approach to a selection of each stage -
specific genes. The 83 genes specific for ISACHC class 1
were identified (data not shown). The list of ISACHC
class 2 - specific genes was the longest and consisted on
1247 genes (data not shown). In cases of most advanced
disease, ISACHC 3, the list of specific genes was 200
(data not shown). These four lists of genes were sub-
jected to further analysis.
Pathways connected with differentially expressed genes
Next we examined the differentially regulated genes for
enrichment in any known canonical pathway. For this
purpose the Pathway Studio software was used. The
most interesting results were obtained from analysis of
the Ariadne Receptor Signaling Pathways. The results of
this analysis are presented in Tables 3, 4, 5, 6.
Real-time RT-PCR
To validate microarray data we selected three genes for
Real-time PCR analysis (ACTA2, TIMP1, MMP8). The
changes in the expression of these three genes measured
using Real-time qPCR were similar to gene expression
changes observed in the microarray studies (Figures 1, 2, 3).
Discussion
Heart failure in dogs does not occur as frequently as it
does in humans and is mainly caused by two diseases,
Table 2 The list of the differentially regulated heart-failure-specific genes in dogs with ISACHC heart failure
GeneSymbol Adjusted p-values Regulation Description
ACTA1 0.014573121 Up Actin, alpha 1, skeletal muscle
ACTA2 0.039442863 Up Actin, alpha 2, smooth muscle, aorta
ACTC1 0.024042822 Up Actin, alpha, cardiac muscle 1
ACTL7A 0.024659734 Up Actin-like 7A
ADA 0.01982955 Up Adenosine deaminase F
ATF4 0.044055864 Up Activating transcription factor 4
CAMP 0.018274972 Up Cathelicidin antimicrobial peptide
CAPG 0.046687745 Up Capping protein (actin filament), gelsolin-like
CCL14 0.024452273 Up Chemokine (C-C motif) ligand 14
CD151 0.012394691 Up CD151 molecule (Raph blood group)
CD177 0.010730711 Up CD177 molecule
CD300E 0.0064891023 Up CD300e molecule
CORO1B 0.03894925 Up Coronin, actin binding protein, 1B
CRYL1 0.0078813145 Up Crystallin, lambda 1
CYBA 0.031601883 Up Cytochrome b-245, alpha polypeptide
CYP27A1 0.034636706 Up Cytochrome P450, family 27, subfamily A, polypeptide 1
DPEP2 0.008431375 Up Dipeptidase 2
DSTN 0.008163466 Up Destrin (actin depolymerizing factor)
EAF1 0.03957692 Up ELL associated factor 1
EPHX2 0.018156866 Up Epoxide hydrolase 2, cytoplasmic
FAM107A 0.020942843 Up Family with sequence similarity 107, member A
FANCG 0.0043643974 Down Fanconi anemia, complementation group G
FLOT2 0.017366651 Up Flotillin 2
GP9 0.0075741783 Up Glycoprotein IX (platelet)
GSN 0.006870092 Up Gelsolin
HK3 0.0073725334 Up Hexokinase 3 (white cell)
HP 0.016630936 Up Haptoglobin
HPCAL1 0.030948874 Up Hippocalcin-like 1
IL10RA 0.046400532 Up Interleukin 10 receptor, alpha
KDELR1 0.0037026592 Up KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1
KLHDC8B 0.015807072 Up Kelch domain containing 8B
LOC475113 0.008475645 Up Lymphocyte antigen 6B-like
LOC491090 0.027546933 Up Similar to tubulin, alpha 1
LSM10 0.0052581653 Up LSM10, U7 small nuclear RNA associated
MAPK1 0.03080859 Up Mitogen-activated protein kinase 1
ME1 0.016186723 Up Malic enzyme 1, NADP(+)-dependent, cytosolic
MMP8 0.008103578 Up Matrix metallopeptidase 8 (neutrophil collagenase)
MMRN1 0.005678207 Up Multimerin 1
MOV10L1 0.012869541 Up Mov10l1, Moloney leukemia virus 10-like 1, homolog (mouse)
MRPL37 0.026399544 Up Mitochondrial ribosomal protein L37
MVP 0.008610116 Up Major vault protein
MYL6 0.032878894 Up Myosin, light chain 6, alkali, smooth muscle and non-muscle
MYL6B 0.008475645 Up Myosin, light chain 6B, alkali, smooth muscle and non-muscle
N4BP2 0.01824313 Down NEDD4 binding protein 2
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Table 2 The list of the differentially regulated heart-failure-specific genes in dogs with ISACHC heart failure (Continued)
NAGPA 0.038744777 Up N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase
NEIL1 0.030278882 Down Nei endonuclease VIII-like 1 (E. coli)
NQO2 0.037860617 Up NAD(P)H dehydrogenase, quinone 2
NRGN 0.014320144 Up Neurogranin (protein kinase C substrate, RC3)
NSG1 0.009202879 Up Neuron specific gene family member 1
PARVB 0.025306692 Up Parvin, beta
PCGF2 0.015807072 Up Polycomb group ring finger 2
PGLYRP1 0.0151561815 Up Peptidoglycan recognition protein 1
PPP1R3D 0.0077612605 Up Protein phosphatase 1, regulatory (inhibitor) subunit 3D
PTGER3 0.0045230556 Up Prostaglandin E receptor 3 (subtype EP3)
PTPN9 0.008163466 Up Protein tyrosine phosphatase, non-receptor type 9
RSU1 0.046061113 Up Ras suppressor protein 1
SEPT5 0.0062189046 Up Septin 5
SHC2 0.02669537 Up SHC (Src homology 2 domain containing) transforming protein 2
SLC11A1 0.0045230556 Up Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1
SLC27A2 0.006745509 Up Solute carrier family 27 (fatty acid transporter), member 2
SLC2A6 0.0045230556 Up Solute carrier family 2 (facilitated glucose transporter), member 6
TBC1D30 0.030404283 Up TBC1 domain family, member 30
TBXAS1 0.0049617672 Up Thromboxane A synthase 1 (platelet)
TCIRG1 0.023556981 Up T-cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 subunit A3
TIMP1 0.0043643974 Up TIMP metallopeptidase inhibitor 1
TOP3B 0.02519754 Up Topoisomerase (DNA) III beta
TRPV2 0.0049617672 Up Transient receptor potential cation channel, subfamily V, member 2
TSPO 0.004600876 Up Translocator protein (18 kDa)
TTC19 0.0075741783 Down Tetratricopeptide repeat domain 19
VNN1 0.031601883 Down Vanin 1
ZNF248 0.004831977 Down Zinc finger protein 248
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valve disease or chronic degenerative valvular disease)
and dilated cardiomyopathy. Both these diseases can lead
to congestive heart failure and the associated clinical
signs. Since the molecular background of these diseases,
especially endocardiosis, is still far from fully elucidated,
the search for any specific markers (prognostic, thera-
peutic) of this disease would be of great value.
In the present study we evaluated the transcriptomic
profile of peripheral blood nuclear cells of dogs withTable 3 Ariadne pathways based on heart-failure-specific







EphrinR - > actin signaling ACTA2, GSN, ACTA1, ACTC1,
DSTN
0.0179871
AngiotensinR - > CREB/ELK-SRF/
TP53 signaling
MAPK1, CYBA, NQO2 0.0359593different stages of heart disease. Since the whole analysis
resulted in the huge number of differentially expressed
transcripts (4579) we decided to identify two types of
genes - 1) genes differentially expressed in all affected
dogs, despite the ISACHC stage (so called heart-failure-
specific genes) and 2) genes differentially expressed in
each of ISACHC stages (so called ISACHC stage-specific
genes). This approach seems reasonable because if the
gene is regulated in all patients with heart failure, despite
the stage of the disease, it could be a potential marker ofTable 4 Ariadne pathways based on ISACHC1-specific







PTPRC - > BCL6 signaling 2 0.0221563
BradykininR - > STAT3 signaling 1 0.0349728
TNFR - > AP-1/ATF/TP53 signaling 2 0.0462323
Table 5 Ariadne pathways based on ISACHC2-specific







UrokinaseR - > ELK-SRF signaling 9 0.0010517
IL4R - > ELK-SRF/HMGY signaling 9 0.00118083
PDGFR - > FOXO3A signaling 5 0.00176524
IL2R - > ELK-SRF/MYC signaling 8 0.00234544
AGER - > NF-kB signaling 6 0.00241572
IL15R - > NF-kB/NFATC signaling 6 0.0028208
IL7R - > FOXO/NF-kB signaling 6 0.00327501
InsulinR - > CTNNB/FOXA/FOXO
signaling
5 0.0038699
FibronectinR - > CTNNB signaling 6 0.00434523
TNFRSF5/13B - > NFATC1 signaling 5 0.00459712
VEGFR - > CTNNB signaling 5 0.00459712
PTPRC - > STAT6 signaling 2 0.00520887
FGFR - > AP-1/CREB/CREBBP/ELK-SRF/MYC
signaling
10 0.00699557
HGFR - > FOXO3A signaling 4 0.00709744
AdenosineR - > NF-kB signaling 7 0.0071087
ErythropoietinR - > FOXO3A signaling 4 0.00859443
TLR3 - > NF-kB signaling 3 0.00948063
ICAM2 - > CTNNB/FOXO/STAT3 signaling 5 0.00974526
CD19 - > NF-kB signaling 5 0.00974526
InsulinR - > ELK-SRF/SREBF signaling 7 0.0104641
FibronectinR - > AP-1/ELK-SRF/SREBF
signaling
10 0.0106044
Notch - > NF-kB signaling 5 0.0111183
GHR - > NF-kB signaling 5 0.0111183
IL12R - > NF-kB/NFATC signaling 5 0.0126187
DopamineR2 - > NF-kB signaling 5 0.0126187
ThrombinR - > NF-kB signaling 5 0.0126187
ErythropoietinR - > NF-kB signaling 6 0.0138912
AGER - > CREB/SP1 signaling 5 0.0142517
AngiopoietinR - > FOXO signaling 4 0.0142826
VEGFR - > FOXO3A signaling 4 0.0166053
CholinergicRm - > CREB/ELK-SRF
signaling
10 0.0174704
B-cell receptor - > NFATC signaling 5 0.0179347
ErythropoietinR - > AP-1/CREB/MYC
signaling
8 0.0182859
EDG2 - > ELK-SRF signaling 7 0.0189356
SerotoninR1 - > FOS signaling 10 0.019617
HGFR - > AP-1/CREB/MYC signaling 8 0.0209776
IGF1R - > CEBPA/FOXO1A signaling 4 0.0219319
FcIgER - > ELK-SRF signaling 7 0.0220582
TLR1/2/6 - > NF-kB signaling 5 0.0222033
Table 5 Ariadne pathways based on ISACHC2-specific
genes differentially regulated in dogs with ISACHC2
heart failure (Continued)
DopamineR2 - > AP-1/CREB/ELK-SRF
signaling
9 0.024631
GDNF - > HSF1 signaling 7 0.025526
ThrombopoietinR - > AP-1/CREB/ELK-
SRF/MYC signaling
8 0.0255337
VEGFR - > AP-1/CREB/MYC signaling 8 0.0289362
MacrophageR - > CEBPB/NF-kB signaling 5 0.0326186
TLR3 - > IRF signaling 2 0.0326546
FibronectinR - > NF-kB signaling 6 0.032985
GHR - > ELK-SRF/MYC signaling 6 0.0355346
B-cell receptor - > NF-kB signaling 6 0.0382096
CholinergicRn - > CREB signaling 5 0.0388136
NTRK - > FOXO/MYCN signaling 4 0.0394373
EGFR - > AP-1/CREB/ELK-SRF/MYC
signaling
8 0.0410289
IL6R - > STAT signaling 2 0.0423644
PDGFR - > AP-1/MYC signaling 7 0.043159
CD38 - > NF-kB signaling 7 0.043159
KIT - > MITF signaling 6 0.043943
NTRK - > AP-1/CREB/ELK-SRF/MYC/
SMAD3/TP53 signaling
8 0.0457237
PTAFR - > AP-1/ATF1/CREB/ERK-SRF
signaling
9 0.0466592
IGF1R - > MEF/MYOD/MYOG signaling 6 0.0470043
CD19 - > AP-1/ELK-SRF signaling 6 0.0470043
PTAFR - > NF-kB signaling 6 0.0470043
ThrombopoietinR - > SPI1 signaling 4 0.0481701
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of each ISACHC stage-specific gene give the opportunity
to identify markers of heart disease progression (i.e. form
stage I to stage II or from stage II to stage III).
The list of heart-failure specific genes included 117
transcripts for which we were able to identify 71
specific genes. Among these genes we were able to
identify three α-SMA genes which are considered as a
markers of muscle cells. This phenomenon could suggest
the presence of myofibroblasts (circulating fibroblasts)
in the peripheral blood nuclear cells of dogs with heart
failure. Similar observation has been recently published
in humans with atrial fibrillation what could indicate
that heart disease could be related with the presence
of α-SMA containing cells in the blood [17]. However,
α-SMA containing cells could also be of hematopoietic
progenitor cells origin so their source in the blood of
heart disease patients is still unclear [18]. Moreover,
our results of flow cytometer analysis showed that
the percentage of α-SMA positive cells in peripheral
Table 6 Ariadne pathways based on ISACHC3-specific







HGFR - > FOXO3A signaling 3 0.00563574
ERBB2/3 - > EP300/ETS/ETV/SP1 signaling 5 0.01015
EGFR/ERBB2 - > HIF1A signaling 5 0.0128385
TNFRSF5/13B - > NFATC1 signaling 3 0.0152928
HGFR - > AP-1/CREB/MYC signaling 5 0.0216208
AdenosineR - > NF-kB signaling 4 0.0217062
ICAM2 - > CTNNB/FOXO/STAT3 signaling 3 0.0242659
NeurotensinR - > ELK-SRF/AP-1/EGR
signaling
5 0.0248821
IL2R - > ELK-SRF/MYC signaling 4 0.0259176
InsulinR - > ELK-SRF/SREBF signaling 4 0.0274252
GHR - > ELK-SRF/MYC signaling 4 0.0274252
KIT - > MITF signaling 4 0.032265
IGF1R - > MEF/MYOD/MYOG signaling 4 0.033985
UrokinaseR - > ELK-SRF signaling 4 0.0357589
IL4R - > ELK-SRF/HMGY signaling 4 0.0375869
FibronectinR - > CTNNB signaling 3 0.0381165
EDG2 - > ELK-SRF signaling 4 0.0394692
EGFR/ERBB3 - > MEF/MYOD/NFATC/
MYOG signaling
6 0.0414187
FcIgER - > ELK-SRF signaling 4 0.0433973
EGFR - > NCOR2 signaling 4 0.0454432
GDNF - > HSF1 signaling 4 0.047544
ErythropoietinR - > ELK-SRF/FOS signaling 5 0.0477064
Figure 1 The expression TIMP1 gene measured with microarray
and Real-time PCR in dogs with different ISACHC stages of
heart disease.
Figure 2 The expression MMP8 gene measured with microarray
and Real-time PCR in dogs with different ISACHC stages of
heart disease.
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class 2 heart failure was between 0.2-0.5% (Additional
files 1, 2). Whether these cells could be a marker of
heart disease remains a pure speculation. Other genes
present among 71 heart failure specific genes have been
previously related to heart failure or involved in heart
disease development. Examples include matrix metallo-
peptidase 8 (MMP8) and TIMP metallopeptidase inhibi-
tor 1 (TIMP1). It is known that remodelling of the
extracellular matrix (ECM) occurs during heart failure
and the matrix metalloproteinases and their tissue inhibi-
tors are involved in this process [19]. Initially MMP-8
was considered to be only expressed in peripheral in-
flammatory cells, but its myocardial sources could be
endogenous cell types such as mast cells [20]. The level
of MMP8 is increased during left ventricular remodelling
following myocardial infarction in rats [21]. Our study
showed that the expression of MMP8 is increased in allFigure 3 The expression ACTA2 gene measured with microarray
and Real-time PCR in dogs with different ISACHC stages of
heart disease.
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(over a 4 fold change). Moreover, these results were
confirmed with Real-time PCR (Figure 2). The study
conducted by Oyama and Chittur revealed that the
expression of TIMP1 was over 4 times higher in dogs
with endocardiosis than in healthy dogs [4]. Our results
(both microarray and Real-time PCR) showed a similar
tendency. Another gene identified as heart - failure -
specific one was haptoglobin (HP). The expression of
HP was higher (over 2.4 fold change) in diseased dogs
than in control dogs. In humans the functional allelic
polymorphism in the HP gene plays a key role in deter-
mining survival and presence of congestive heart failure
after myocardial infarction [22]. However, it seems quite
impossible that single gene expression could influence
the complex processes of heart disease development. Ra-
ther relationships and interactions between differentially
expressed genes could play a key role. In order to evalu-
ate these possibilities we used the Pathway Studio soft-
ware. This database gives the opportunity to find genes
involved in different kinds of signalling pathways. Pathway
Studio software can also group differentially expressed
genes on the basis of their molecular function and bio-
logical processes in which they are involved. The genes
differentially expressed with statistical significance identi-
fied as heart-failure-specific were involved in regulation of
two canonical pathways, namely angiotensinR - > CREB/
ELK-SRF/TP53 signalling and ephrinR - > actin signalling.
The first signalling pathway shows the relation between
the expression of angiotensin receptors and CREB/ELK-
SRF/TP53 transcription factors and indicates that the
combined activation of CREB/ELK-SRF/TP53 leads to
angiotensin receptor activation during the disease process.
Serum response factor (SRF) is a transcription factor which
regulates many immediate-early genes and is required for
the appearance of beating sarcomeres in the heart [23]. SRF
activates genes involved in smooth muscle differentiation
and proliferation by recruiting muscle-restricted cofactors,
such as ternary complex factors (TCFs) of the ETS-domain
family, for example ELK-1 [24]. Changed expression of
ELK-4 in peripheral blood nuclear cells in patients with
refractory ischemic end-stage heart failure were also seen in
our previous study [25] and Kuner et al. recognized ELK-4
as potential interaction partner necessary for creating net-
work of regulatory genes in ischemic cardiomyopathy [26].
Since CREB/ELK-SRF/TP53 transcription factors target
angiotensin receptors in dogs with heart failure, it clearly
proves that the function of the failing heart is directly corre-
lated with renal function and that in cases of heart disease
we could observe changes in the function of renin-
angiotensin-aldosterone axis. Such a conclusion was also
drawn from one of our previous studies in which we were
able to identify that transcriptomic profile of peripheral
blood nuclear cells in humans after acute heart failure iscorrelated with the creatinine (marker of kidney function)
level in the blood [27].
Since the lists of genes specific for each heart failure
stage were much longer than the list of heart-failure-
specific genes we also ran the Pathway Studio analysis to
obtain information on significantly regulated signalling
pathways in each ISACHC stage (Tables 4, 5, 6). While
analysing these results one has to remember that ISACHC
1 heart failure stage encompasses patients without clinical
signs of heart disease, ISACHC 2 stage includes dogs with
compensated clinical signs and ISACHC 3 stage includes
dogs with uncompensated heart failure. Having this in
mind one could conclude the very long list of differentially
regulated genes as well as significantly regulated signalling
pathways in ISACHC 2 patients is not only the results of
heart disease but also the result of many different com-
pensatory mechanisms which were triggered in order to
restore homeostasis. On the other hand in ISACHC 3 pa-
tients, the majority of these mechanisms are no longer in
place so the list of regulated genes and pathways is much
shorter. Based on our results it could be concluded that
for the ISACHC 1 group, the specific changes in the tran-
scriptome include the regulation of protein tyrosine phos-
phatase kinase receptors, bradykinin receptor and tumor
necrosis factor receptor. These changes seem to be rather
unspecific for heart disease and probably reflect only the
reaction of the body to progressed disease, not the pro-
gression of the disease itself. In case of ISACHC 2 specific
genes and pathways the interpretation of the obtained
results is complex but in our opinion it is worth to point
out that in addition to the statistically significant regula-
tion of many inflammatory pathways and growth factors,
we also see changes in the regulation of transcription fac-
tors targeted at platelet-mediated mediators and PTAFR
(platelet-activating factor receptor). Anti-platelet therapy
is one of the standard approaches in the treatment of
patients with heart failure in humans and the regulation
of this receptor was also identified in our previous study
on patients with end-stage ischemic heart failure [25].
Platelet-activating factor may play a critical role in the
development of severe heart failure coupled with resulting
multiple organ failure, as seen in the Munakata et al. study
performed on dogs with left ventricular assistance post
coronary ligation [28]. This study showed that it may also
be beneficial for dogs with clinical signs of severe heart
disease to receive some form of anti-platelet therapy.
In the pathways significantly regulated in ISACHC 3
patients, we were able to identify for the first time the
presence of transcription factors targeting EGFR/ERBB2.
The ErbB2(HER2)-dependent signalling pathway is in-
volved in proper myocardium function, structure and
contractility [29-31]. The ErbB2 (HER2) receptor is re-
sponsible for the activation of several transcription fac-
tors, including AP-1 (also in heart muscle hypertrophy)
Hulanicka et al. BMC Genomics 2014, 15:509 Page 8 of 11
http://www.biomedcentral.com/1471-2164/15/509and nuclear factor kappa B (involved in the response to
oxidative stress) [32]. It could play a key role in dilated
cardiomyopathy prevention [33]. In mice with ErbB2
gene deletion a gradual development of systolic myocar-
dial dysfunction has been observed, occurring with myo-
cardium thinning and heart ventricles distension [34]. In
mice the binding of neuregulin-1 (NRG-1) to the HER2
receptor is cardioprotective [35]. Since there is no data
in the literature in this field obtained from dogs, we
could only speculate that the regulation of ErbB2 signal-
ling pathway in dogs with ISACHC 3 heart failure could
be the feature of end-stage heart failure also in this spe-
cies. But this observation requires further investigation.
Conclusions
The transcriptomic profile of peripheral blood nuclear
cells in dogs with heart failure seems to reflect the pres-
ence of clinical signs of the disease in patients. Such a
conclusion could be drawn from the observation that
the longest list of differentially expressed genes as well
as signalling pathways were identified in ISACHC 2
group of patients, those first to show clinical signs of
heart failure. The development of heart failure in dogs
results in changed expression of genes involved in the
regulation of the renin-angiotensin-aldosterone axis in
peripheral blood nuclear cells whereas end-stage heart
failure could be reflected by activation of transcription
factors targeting at the ErbB2 receptor.
Methods
Animals
This study complies with national and institutional guide-
lines on the use of animals in clinical research according
to the Polish legal act from January 21st, 2005 (Ustawa o
doświadczeniach na zwierzętach z dnia 21 stycznia 2005 r.
(Dz. U. z 2005 r. Nr 33, poz. 289 z późn.zm.)), concerning
experiments performed on client owned animals. Be-
fore enrolling a dog into the study an informed consent
from its owner was obtained and a high standard of
care was adhered to throughout each examination. A
prospective analysis and studies were carried out on
dogs submitted to the Cardiology Service of the Small
Animal Clinic, Faculty of Veterinary Medicine, School
of Agriculture in Warsaw. The clinical picture of the
animals included: animal history, clinical examination,
echocardiographic examination and where applicable
electrocardiographic and radiographic examinations.
Dogs with recognized heart disease were classified
according the ISACHC (International Small Animal
Cardiac Health Council) classification scheme as class 1
(asymptomatic) - 13 dogs, class 2 (mild to moderate heart
failure) - 13 dogs and class 3 (severe heart failure) - 12
dogs. The control group consisted of 14 healthy dogs.
Study population characteristics are shown in Table 7.Statistical analyses of clinical parameters were performed
using GraphPad Prism version 5.00 (GraphPad Software,
Inc., USA).
Clinical and laboratory examinations
The clinical and laboratory examinations included: complete
physical examination, including thoracic auscultation, as-
sessment of dyspnoea, cough, heart rate, presence of heart
murmurs, mucosal membrane colour, pulse, palpation of
thorax and abdomen as well as additional cardiologic
examinations: echocardiography, electrocardiography (I,
II,III, aVL, aVF and aVR leads) in dogs with arrhythmias,
radiography in dogs with suspicion of congestive heart fail-
ure, and blood pressure measurement (Doppler method).
All of above mentioned examinations were carried out by
one clinician from the Cardiology Service of Small Animal
Clinic at Faculty of Veterinary Medicine. The blood
morphology and biochemistry analyses were conducted in
the Laboratory of Small Animal Clinic.
All examinations were performed at rest without pharma-
cological restraint. A transthoracic echocardiographic (TTE)
examination was performed in all dogs with an Aloka
4000 ultrasound machine equipped with a cardiology pro-
grams and 2.5 - 7-megahertz (mHz) sector transducers.
Electrocardiographic examination (leads I, II, III, aVL, aVF
and aVR) were performed with a BTL-08 MD machine.
Radiological examination of the chest were performed
with the G&E Prestige II X-ray machine. The blood
samples for the transcription profile analysis were col-
lected from client-owned dogs during routine veterinary
examinations.
RNA isolation, validation, labelling, and hybridization
Blood samples were drawn from the cephalic or jugular
veins and collected in Rneasy Protect Animal Blood
Tubes (Qiagen, USA). Total RNA from peripheral blood
nuclear cells was isolated using a Rneasy Protect Animal
Blood Kit (Qiagen, USA). Isolated RNA samples were
dissolved in 30 μl of REB Buffer from the test kit. Next
the RNA quantity was measured spectrophotometrically
using a NanoDrop (NanoDrop Technologies, USA). The
analysis of final RNA quality and integrity was per-
formed with a BioAnalyzer (Agilent, USA). To ensure
optimal data quality, only RNA samples with RIN num-
ber ≥7.5 were included in the analysis.
The analysis of gene-expression profile was performed
using Canine (V2) Gene Expression Microarray, 4x44K
(Agilent Technologies, USA). Each slide contained 4 mi-
croarrays representing about 45000 canine predicted
mRNAs. The Quick Amp Labeling Kit (Agilent, USA)
was used to amplify and label target RNA to generate
complementary RNA (cRNA) for oligo microarrays used
in gene expression profiling. Experiment was performed
using a common reference design, where the common
Table 7 Study population characteristics (data are shown as mean ± SD)
ISACHC Healthy ISACHC 1 ISACHC 2 ISACHC 3
n = 52 14 13 13 12
Breeds Dachshund (5), German Shepherds (6),
Labrador retriever (1), German Pointer
(1), Rottweiler (1)
Dachshund (10), Labrador retriever
(1), Miniature poodle (1), Standard
schnauzer (1)
Dachshund (9), Cocker spaniel
(2), Airedale terrier (1), Standard
schnauzer (1)
Dachshund (12)
Age range 1.4 - 10.5 years 5.75 - 14.0 years 9.8 - 15.2 years 7.25 - 15.2 years
Sex
Males 8 7 7 10
Females 6 6 6 2
EF 66.08 ± 7.99 72.93 ± 9.33 77.0 ± 8,90** 83.08 ± 4.96***
HR 107.3 ± 18.90 113.7 ± 26.08 134.0 ± 21.29* 140.7 ± 19.43**
*Statistically significant difference vs healthy dogs with p<0.05; **statistically significant difference vs healthy dogs with p<0.01; ***statistically significant
difference vs healthy dogs with p<0.001.
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healthy dogs. On each two-color microarrays, we hybrid-
ized 825 ng of cRNA from the pool (labelled Cy3) and
825 ng of cRNA (labelled Cy5). In total we ran 52 microar-
rays - one for each patient. Microarray hybridization was
performed with the Gene Expression Hybridization Kit
(Agilent Technologies, USA), according to the manufac-
turer's protocols. RNA Spike In Kit (Agilent Technologies,
USA) was used as an internal control. Acquisition and
analysis of hybridization intensities were performed using
the Agilent DNA microarray scanner.
Signal detection and statistical analysis
Data were extracted and background subtracted using
the standard procedures contained in the Agilent Fea-
ture Extraction (FE) Software version 10.7.3.1. FE per-
forms a Lowess normalization. The statistical analysis
was performed using Gene Spring 12 software (Agilent,
USA). The samples underwent quality control and the
results showed that each sample had a similar QC metric
profile. The next step was filtering probesets by flags to
remove poor quality probes (absent flags). The statistical
significance of the differences was evaluated using a one-
way ANOVA and Tukey's HSD Post-hoc test (p < 0.05). A
multiple testing correction was performed using Benjamini
and Hochberg False Discovery Rate (FDR) < 5%. Micro-
array data were deposited at the Gene Expression Omnibus
data repository under the number GSE48319 and followed
MIAME requirements.
To identify signalling pathways and gene function the





GAPDH CTGGGGCTCACTTGAAAGG(Ariadne Genomics). This is a database consisting of
millions of individually modelled relationships between
proteins, genes, complexes, cells, tissues, drugs and
diseases [36].
Real-time RT-PCR
To verify microarray results on the expressions of ACTA2
(the gene for the actin, alpha 2, smooth muscle, aorta),
MMP8 (the gene for the matrix metallopeptidase 8 (neu-
trophil collagenase)), TIMP1 (the gene for the TIMP
metallopeptidase inhibitor 1) were checked by real-time
RT-PCR. The sequences of these genes were obtained
from the Ensembl database. Primers were designed using
Primer-Blast software (NCBI database) and then checked
for secondary structures using Oligo Calculator (free on-
line access). The secondary structures of the amplicon
were examined using the mfold Web Server (free on-line
access). GAPDH was used as a house keeping gene [37].
The sequences of the primers are listed in Table 8.
cDNA was synthesized using the Enhanced Avian HS
RT-PCR Kit (Sigma-Aldrich, St. Louis, Missouri). All
analyses were performed on individual samples of total
RNA using a LightCycler FastStart DNA Master SYBR
Green I kit (Roche Diagnostics GmBH, Germany) as fol-
lows: Mg2+ was added to a final concentration of 3 mM;
pre-incubation at 95°C for 10 minutes; amplification
(40 cycles) including denaturation at 95°C for 10 seconds,
annealing – temperature and time specified in Table 8;
melting curve including denaturation at 95°C for 0 sec-
onds, annealing at 65°C for 15 seconds, continuous
melting at 95°C for 0 seconds (slope = 0.1°C/s); coolingReverse Annealing conditions
GAAAGCACCGCCTGAATAG 60°C for 9 s
TTGCTTGAAGGACCGTAGAT 60°C for 10 s
GGGGATGGATGAACAGGTAA 60°C for 10 s
CAAACATGGGGGCATCAG 59°C for 4 s
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2-ΔΔCT method [38].
Additional files
Additional file 1: Representative results of flow cytometric analysis
showing negative control of immunofluorescence staining of
peripheral blood mononuclear cells (PBMC) from dog number 1
with ISACHC 2 class heart failure. PBMC were fixed, permeabilized and
stained with secondary antibodies: chicken anti-mouse IgG conjugated with
Alexa Fluor 488 (Molecular Probes, Life Technologies). The percentage of
α-SMA positive cells is 0.0%; a) morphological flow cytometric parameters of
analyzed cells gated on the basis of their size (forward scatter: FSC) and
granularity (side scatter: SSC); b) cytogram of Alexa Fluor 488 positive cells
(gate P2); c) histogram of Alexa Fluor 488 positive cells (gate P4); d) table
showing population hierarchy of cells in cytograms a, b, and histogram c.
Additional file 2: Representative results of flow cytometric analysis
of peripheral blood mononuclear cells (PBMC) from dog number
1 with ISACHC 2 class heart failure, which were stained with
antibodies against alpha smooth muscle actin (α-SMA). PBMC were
fixed, permeabilized and stained with monoclonal mouse anti- α-SMA
antibodies (clone 1A4, Dako, Denmark), followed by incubation with
secondary antibodies: chicken anti-mouse IgG conjugated with Alexa Fluor
488 (Molecular Probes, Life Technologies). The percentage of α-SMA positive
cells is around 0.3%; a) morphological flow cytometric parameters of
analyzed cells gated on the basis of their size (forward scatter: FSC) and
granularity (side scatter: SSC); b) cytogram showing α-SMA –positive cells
gated in gate P2; c) histogram showing α-SMA –positive cells gated in gate
P4; d) table showing population hierarchy of cells in cytograms a, b, and
histogram c.
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